Vanberra Signal
Free trial

OrphAI Therapeutics

Curated by Signal

Developer of treatments for rare orphan conditions

Life Sciences Technologyorphai-therapeutics.com

Overview

Developer of treatments for rare orphan conditions. It offers AI-based platform for drug development which includes AIT-101 for amyotrophic lateral sclerosis, LAM-001 for Pulmonary Arterial Hypertension, Bronchiolitis Obliterans Syndrome, and Pulmonary Sarcoidosis, and AIT-102 for oncology indications.

Key facts

Founded
2013
Headquarters
Guilford, United States
Stage
Sign up to view
Industry
Life Sciences Technology

Business model

3 products and services
Sign up to view

Contact

Primary office
Sign up to view

More on Vanberra Signal

Members only
Business overviewCore metrics and financialsPeopleLeadership and key peopleSimilar companiesPeers and competitorsDeep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

  • Identifeye Health

    Developer of a non-invasive test to detect health conditions through the eyes

    Life Sciences TechnologyGuilford, United States

  • Aprecia Pharmaceuticals

    Develops & manufactures orodispersible formulations of highly prescribed high-dose medications using proprietary drug delivery systems.

    Life Sciences TechnologyLanghorne, United States

  • EEG NOW

    Provider of point-of-care EEG devices

    Life Sciences TechnologyGainesville, United States

About OrphAI Therapeutics

What does OrphAI Therapeutics do?

Developer of treatments for rare orphan conditions.

Where is OrphAI Therapeutics headquartered?

OrphAI Therapeutics is headquartered in Guilford, United States.

When was OrphAI Therapeutics founded?

OrphAI Therapeutics was founded in 2013.

Which sector is OrphAI Therapeutics in?

OrphAI Therapeutics operates in Life Sciences Technology.

Who are OrphAI Therapeutics's competitors?

Companies similar to OrphAI Therapeutics include Identifeye Health, Aprecia Pharmaceuticals, and EEG NOW.